Dr Massimiliano Spaliviero, MD | |
Hsc Level 9 Urology, Room 040, Stony Brook, NY 11794-8093 | |
(631) 444-3642 | |
(631) 444-6410 |
Full Name | Dr Massimiliano Spaliviero |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 27 Years |
Location | Hsc Level 9 Urology, Stony Brook, New York |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962522318 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 268507 (New York) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Suny/stony Brook University Hospital | Stony brook, NY | Hospital |
St Charles Hospital | Port jefferson, NY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Stony Brook Urology University Faculty Practice Corporation | 3577454008 | 34 |
News Archive
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.
A new study suggests that an intervention to reduce supine sleep in late pregnancy may promote maternal and fetal health.
In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.
› Verified 8 days ago
Entity Name | Mskcc Surgery Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699766261 PECOS PAC ID: 0345131405 Enrollment ID: O20040320000446 |
News Archive
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.
A new study suggests that an intervention to reduce supine sleep in late pregnancy may promote maternal and fetal health.
In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.
› Verified 8 days ago
Entity Name | Stony Brook Urology University Faculty Practice Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1538114707 PECOS PAC ID: 3577454008 Enrollment ID: O20040323001255 |
News Archive
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.
A new study suggests that an intervention to reduce supine sleep in late pregnancy may promote maternal and fetal health.
In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Massimiliano Spaliviero, MD Hsc Level 9 Urology, Room 040, Stony Brook, NY 11794-8093 Ph: (631) 444-2348 | Dr Massimiliano Spaliviero, MD Hsc Level 9 Urology, Room 040, Stony Brook, NY 11794-8093 Ph: (631) 444-3642 |
News Archive
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.
A new study suggests that an intervention to reduce supine sleep in late pregnancy may promote maternal and fetal health.
In 2001, Mount Sinai researchers published a study in Science that showed that a gene, known as KLF6, fails to function properly in at least 50 to 60 percent of all prostate cancers. This was the first single gene shown to be responsible for the majority of cases of this disease, which affects approximately 200,000 men each year.
› Verified 8 days ago
Dr. Justina Tam, M.D. Urology Medicare: Medicare Enrolled Practice Location: Stony Brook Urology, Hsc T-9 Room 040, Stony Brook, NY 11794 Phone: 631-444-6270 Fax: 631-444-7620 | |
Dr. William Travis Berg, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 101 Nicolls Road, Hsc T9-040, Stony Brook, NY 11794 Phone: 631-444-1910 | |
Dr. Jason Michael Kim, MD Urology Medicare: Accepting Medicare Assignments Practice Location: Department Of Urology Hsc 9, Stony Brook University Medical Center, Stony Brook, NY 11794 Phone: 631-444-1916 Fax: 631-444-7620 | |
Dr. Chris Du, Urology Medicare: Medicare Enrolled Practice Location: 101 Nicolls Road, Hsc T-9 Room 040, Stony Brook, NY 11794 Phone: 626-444-1916 Fax: 631-444-3765 | |
Michael Louis Ernst, MD Urology Medicare: Medicare Enrolled Practice Location: 101 Nicholls Rd, Hsc-9 040, Stony Brook, NY 11795 Phone: 631-444-1176 | |
Steven J Weissbart, Urology Medicare: Accepting Medicare Assignments Practice Location: Stony Brook Department Of Urology Hsc 9, Stony Brook, NY 11794 Phone: 631-444-6270 | |
Dr. Albert N Kim, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2500 Nesconset Hwy Bldg 21a, Stony Brook, NY 11790 Phone: 631-751-3000 Fax: 631-509-6559 |